These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35474598)

  • 1. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.
    Jakimovski D; Gibney BL; Marr K; Ramasamy DP; Dwyer MG; Bergsland N; Weinstock-Guttman B; Ramanathan M; Zivadinov R
    Eur J Neurol; 2022 Aug; 29(8):2299-2308. PubMed ID: 35474598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores.
    Jakimovski D; Qureshi F; Ramanathan M; Keshavan A; Leyden K; Jalaleddini K; Ghoreyshi A; Dwyer MG; Bergsland N; Marr K; Weinstock-Guttman B; Zivadinov R
    Mult Scler Relat Disord; 2024 Jul; 87():105687. PubMed ID: 38776599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
    Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1757-1770. PubMed ID: 31437387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
    Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
    Jakimovski D; Benedict RH; Marr K; Gandhi S; Bergsland N; Weinstock-Guttman B; Zivadinov R
    Mult Scler; 2020 Feb; 26(2):201-209. PubMed ID: 30625030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Srpova B; Uher T; Hrnciarova T; Barro C; Andelova M; Michalak Z; Vaneckova M; Krasensky J; Noskova L; Havrdova EK; Kuhle J; Horakova D
    Mult Scler; 2021 Jan; 27(1):52-60. PubMed ID: 31961243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum neurofilament light with microglial activation in multiple sclerosis.
    Saraste M; Matilainen M; Vuorimaa A; Laaksonen S; Sucksdorff M; Leppert D; Kuhle J; Airas L
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):698-706. PubMed ID: 37130728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis.
    Jakimovski D; Bergsland N; Dwyer MG; Ramasamy DP; Ramanathan M; Weinstock-Guttman B; Zivadinov R
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32932824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients.
    Bridel C; Verberk IMW; Heijst JJA; Killestein J; Teunissen CE
    Mult Scler Relat Disord; 2021 Jan; 47():102666. PubMed ID: 33291033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.
    Fabis-Pedrini MJ; Kuhle J; Roberts KMA; Trend S; Jones AP; Maceski A; Carroll WM; Lucas RM; Mastaglia FL; Hart PH; Kermode AG
    Brain Behav; 2022 Feb; 12(2):e2494. PubMed ID: 35084124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.
    Jakimovski D; Bergsland N; Dwyer MG; Choedun K; Marr K; Weinstock-Guttman B; Zivadinov R
    Eur Radiol; 2022 Sep; 32(9):6468-6479. PubMed ID: 35359167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.